Hanyang Med Rev.  2016 May;36(2):113-119. 10.7599/hmr.2016.36.2.113.

Pharmacological Treatments for Tinnitus

Affiliations
  • 1Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. sypak@catholic.ac.kr

Abstract

Pharmacotherapy has been constantly chosen by the clinician among the available treatment options for tinnitus. Medications that have been prescribed off-label to treat tinnitus can be grouped into several categories: benzodiazepines, antidepressants, anticonvulsants, N-methyl-D-aspartate (NMDA) receptor antagonists, dopamine receptor modulators, muscle relaxants, and others. In this article, a wide variety of compounds once used in the treatment of tinnitus and evidenced by clinical trials are reviewed with respect to the mechanisms of action and the drug efficacy. Only a few of the various pharmacological interventions investigated have some beneficial effects against tinnitus: clonazepam, acamprosate, neramexan, and sulpiride. Sertraline and pramipexole were effective in subgroups of patients with psychiatric symptoms or presbycusis. However, no agents have been identified to provide a reproducible long-term reduction of tinnitus in excess of placebo effects. In rodent tinnitus models, L-baclofen, memantine, and KCNQ2/3 channel activators have been demonstrated to reduce tinnitus development. Limitation of the use of an effective high dosage during a longer treatment duration due to dose-dependent side effects of the centrally acting drugs may influence the results in clinical studies. More effective and safer innovative agents should be developed based on the further understanding of tinnitus neural mechanisms and valid animal models, and should be supported by improved clinical trial methodology. The management of tinnitus patients through a tailored treatment approach depending on the detailed classification of tinnitus subtypes will also lead to better treatment outcomes.

Keyword

Anticonvulsant; Antidepressants; Benzodiazepines; Dopamine Receptor Agonist; NMDA Receptor Antagonists

MeSH Terms

Anticonvulsants
Antidepressive Agents
Benzodiazepines
Classification
Clonazepam
Dopamine Agonists
Dopamine Antagonists
Drug Therapy
Humans
Memantine
Models, Animal
N-Methylaspartate
Placebo Effect
Presbycusis
Rodentia
Sertraline
Sulpiride
Tinnitus*
Anticonvulsants
Antidepressive Agents
Benzodiazepines
Clonazepam
Dopamine Agonists
Dopamine Antagonists
Memantine
N-Methylaspartate
Sertraline
Sulpiride

Cited by  1 articles

Tinnitus: Overview
Chul Won Park
Hanyang Med Rev. 2016;36(2):79-80.    doi: 10.7599/hmr.2016.36.2.79.


Reference

1. Ahmad N, Seidman M. Tinnitus in the older adult: epidemiology, pathophysiology and treatment options. Drugs Aging. 2004; 21:297–305.
2. Nondahl DM, Cruickshanks KJ, Huang GH, Klein BE, Klein R, Nieto FJ, et al. Tinnitus and its risk factors in the Beaver Dam offspring study. Int J Audiol. 2011; 50:313–320.
Article
3. Baguley D, McFerran D, Hall D. Tinnitus. Lancet. 2013; 382:1600–1607.
Article
4. Langguth B. Treatment of tinnitus. Curr Opin Otolaryngol Head Neck Surg. 2015; 23:361–368.
Article
5. Jufas NE, Wood R. The use of benzodiazepines for tinnitus: systematic review. J Laryngol Otol. 2015; 129:Suppl 3. S14–S22.
Article
6. Langguth B, Elgoyhen AB. Current pharmacological treatments for tinnitus. Expert Opin Pharmacother. 2012; 13:2495–2509.
Article
7. Lechtenberg R, Shulman A. Benzodiazepines in the treatment of tinnitus. J Laryngol Otol. 1984; 98:271–276.
Article
8. Bahmad FM Jr, Venosa AR, Oliveira CA. Benzodiazepines and GABAergics in treating severe disabling tinnitus of predominantly cochlear origin. Int Tinnitus J. 2006; 12:140–144.
9. Han SS, Nam EC, Won JY, Lee KU, Chun W, Choi HK, et al. Clonazepam Quiets tinnitus: a randomised crossover study with Ginkgo Biloba. J Neurol Neurosurg Psychiatry. 2012; 83:821–827.
Article
10. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double-blind study. Arch Otolaryngol Head Neck Surg. 1993; 119:842–845.
Article
11. Jalali MM, Kousha A, Naghavi SE, Soleimani R, Banan R. The effects of alprazolam on tinnitus: a cross-over randomized clinical trial. Med Sci Monit. 2009; 15:PI55–PI60.
12. Kay NJ. Oral chemotherapy in tinnitus. Br J Audiol. 1981; 15:123–124.
Article
13. Baldo P, Doree C, Molin P, McFerran D, Cecco S. Antidepressants for patients with tinnitus. Cochrane Database Syst Rev. 2012; 9:CD003853.
Article
14. Mihail RC, Crowley JM, Walden BE, Fishburne J, Reinwall JE, Zajtchuk JT. The tricyclic trimipramine in the treatment of subjective tinnitus. Ann Otol Rhinol Laryngol. 1988; 97(2 Pt 1):120–123.
Article
15. Sullivan M, Katon W, Russo J, Dobie R, Sakai C. A randomized trial of nortriptyline for severe chronic tinnitus. Arch Intern Med. 1993; 153:2251–2259.
Article
16. Podoshin L, Ben-David Y, Fradis M, Malatskey S, Hafner H. Idiopathic subjective tinnitus treated by amitriptyline hydrochloride/biofeedback. Int Tinnitus J. 1995; 1:54–60.
17. Bayar N, Boke B, Turan E, Belgin E. Efficacy of amitriptyline in the treatment of subjective tinnitus. J Otolaryngol. 2001; 30:300–303.
Article
18. Robinson SK, Viirre ES, Bailey KA, Gerke MA, Harris JP, Stein MB. Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. Psychosom Med. 2005; 67:981–988.
Article
19. Zöger S, Svedlund J, Holgers KM. The effects of sertraline on severe tinnitus suffering - a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006; 26:32–39.
Article
20. Dib GC, Akemi Kasse C, Alives de Andrade T, Gurgel Testa JR, Cruz OL. Tinnitus treatment with trazodone. Braz J Otorhinolaryngol. 2007; 73:390–397.
Article
21. Hoekstra CE, Rynja SP, van Zanten GA, Rovers MM. Anticonvulsants for tinnitus. Cochrane Database Syst Rev. 2011; 7:CD007960.
Article
22. Donaldson I. Tegretol: a double blind trial in tinnitus. J Laryngol Otol. 1981; 95:947–951.
Article
23. Hulshof JH, Vermeij P. The value of carbamazepine in the treatment of tinnitus. ORL J Otorhinolaryngol Relat Spec. 1985; 47:262–266.
Article
24. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998; 29:233–249.
Article
25. Aazh H, El Refaie A, Humphriss R. Gabapentin for tinnitus: a systematic review. Am J Audiol. 2011; 20:151–158.
Article
26. Witsell DL, Hannley MT, Stinnet S, Tucci DL. Treatment of tinnitus with gabapentin: a pilot study. Otol Neurotol. 2007; 28:11–15.
27. Piccirillo JF, Finnell J, Vlahiotis A, Chole RA, Spitznagel E Jr. Relief of idiopathic subjective tinnitus: is gabapentin effective? Arch Otolaryngol Head Neck Surg. 2007; 133:390–397.
28. Bakhshaee M, Ghasemi M, Azarpazhooh M, Khadivi E, Rezaei S, Shakeri M, et al. Gabapentin effectiveness on the sensation of subjective idiopathic tinnitus: a pilot study. Eur Arch Otorhinolaryngol. 2008; 265:525–530.
Article
29. Ciodaro F, Mannella VK, Cammaroto G, Bonanno L, Galletti F, Galletti B. Oral gabapentin and intradermal injection of lidocaine: is there any role in the treatment of moderate/severe tinnitus? Eur Arch Otorhinolaryngol Relat Spec. 1985; 47:262–266.
Article
30. Simpson JJ, Gilbert AM, Weiner GM, Davies WE. The assessment of lamotrigine, an antiepileptic drug, in the treatment of tinnitus. Am J Otol. 1999; 20:627–631.
31. Kalappa BI, Soh H, Duignan KM, Furuya T, Edwards S, Tzingounis AV, et al. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus. J Neurosci. 2015; 35:8829–8842.
Article
32. Li S, Choi V, Tzounopoulos T. Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus. Proc Natl Acad Sci U S A. 2013; 110:9980–9985.
Article
33. Suckfüll M, Althaus M, Ellers-Lenz B, Gebauer A, Görtelmeyer R, Jastreboff PJ, et al. A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus. BMC Ear Nose Throat Disord. 2011; 11:1.
Article
34. Denk DM, Heinzl H, Franz P, Ehrenberger K. Caroverine in tinnitus treatment. A placebo-controlled blind study. Acta Otolaryngol. 1997; 117:825–830.
35. Domeisen H, Hotz MA, Häusler R. Caroverine in tinnitus treatment. Acta Otolaryngol. 1998; 118:606–608.
Article
36. Azevedo AA, Figueiredo RR. Treatment of tinnitus with acamprosate. Prog Brain Res. 2007; 166:273–277.
Article
37. Sharma DK, Kaur S, Singh J, Kaur I. Role of acamprosate in sensorineural tinnitus. Indian J Pharmacol. 2012; 44:93–96.
Article
38. Figueiredo RR, Langguth B, de Oliveira PM, de Azevedo AA. Tinnitus treatment with memantine. Otolaryngol Head Neck Surg. 2008; 138:492–496.
Article
39. Ralli M, Troiani D, Podda MV, Paciello F, Eramo SL, de Corso E, et al. The effect of the NMDA channel blocker memantine on salicylate-induced tinnitus in rats. Acta Otorhinolaryngol Ital. 2014; 34:198–204.
40. Zheng Y, McNamara E, Stiles L, Darlington CL, Smith PF. Evidence that Memantine Reduces Chronic Tinnitus Caused by Acoustic Trauma in Rats. Front Neurol. 2012; 3:127.
Article
41. Lopez-Gonzalez MA, Esteban-Ortega F. Tinnitus dopaminergic pathway. Ear noises treatment by dopamine modulation. Med Hypotheses. 2005; 65:349–352.
Article
42. Lopez-Gonzalez MA, Santiago AM, Esteban-Ortega F. Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway. J Otolaryngol. 2007; 36:213–219.
Article
43. de Azevedo AA, Langguth B, de Oliveira PM, Figueiredo RR. Tinnitus treatment with piribedil guided by electrocochleography and acoustic otoemissions. Otol Neurotol. 2009; 30:676–680.
Article
44. Sziklai I, Szilvassy J, Szilvassy Z. Tinnitus control by dopamine agonist pramipexole in presbycusis patients: a randomized, placebo-controlled, double-blind study. Laryngoscope. 2011; 121:888–893.
Article
45. Westerberg BD, Roberson JB Jr, Stach BA. A double-blind placebo-controlled trial of baclofen in the treatment of tinnitus. Am J Otol. 1996; 17:896–903.
46. Zheng Y, Vagal S, McNamara E, Darlington CL, Smith PF. A dose-response analysis of the effects of L-baclofen on chronic tinnitus caused by acoustic trauma in rats. Neuropharmacology. 2012; 62:940–946.
Article
47. Smith PF, Zheng Y, Darlington CL. Revisiting baclofen for the treatment of severe chronic tinnitus. Front Neurol. 2012; 3:34.
Article
48. Vanneste S, Figueiredo R, De Ridder D. Treatment of tinnitus with cyclobenzaprine: an open-label study. Int J Clin Pharmacol Ther. 2012; 50:338–344.
Article
49. Coelho C, Figueiredo R, Frank E, Burger J, Schecklmann M, Landgrebe M. Reduction of tinnitus severity by the centrally acting muscle relaxant cyclobenzaprine: an open-label pilot study. Audiol Neurootol. 2012; 17:179–188.
Article
50. Smith PF, Zheng Y, Darlington CL. Ginkgo biloba extracts for tinnitus: More hype than hope? J Ethnopharmacol. 2005; 100:95–99.
Article
51. Drew S, Davies E. Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. BMJ. 2001; 322(7278):73.
Article
52. Rejali D, Sivakumar A, Balaji N. Ginkgo biloba does not benefit patients with tinnitus: a randomized placebo-controlled double-blind trial and meta-analysis of randomized trials. Clin Otolaryngol Allied Sci. 2004; 29:226–231.
Article
53. Miroddi M, Bruno R, Galletti F, Calapai F, Navarra M, Gangemi S. Clinical pharmacology of melatonin in the treatment of tinnitus: a review. Eur J Clin Pharmacol. 2015; 71:263–270.
Article
Full Text Links
  • HMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr